Elicera Q2 FY26 operating loss more than doubles to SEK 6.31 million

• Elicera Therapeutics posted a Q2 operating loss of SEK 6.31 million, widening from SEK 2.89 million a year earlier.
• Net loss deepened to SEK 6.26 million, while operating cash flow improved to an outflow of SEK 3.95 million.
• For January–June, operating loss widened to SEK 11.42 million, while operating cash flow fell to an outflow of SEK 10.93 million.
• A rights issue was subscribed to 75%, raising SEK 54.6 million before transaction costs; the planned size was SEK 72.8 million.
• CARMA study update showed tumor response in 10 of 11 evaluated patients; Johan Liwing was appointed CEO effective Sept. 1, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicera Therapeutics AB published the original content used to generate this news brief via Cision (Ref. ID: 202608280202BITN____UKPR__SV_20260823-BIT-0955-0) on August 28, 2026, and is solely responsible for the information contained therein.